TG Therapeutics, Inc.
TGTX
$42.54
-$0.60-1.39%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 69.56% | 78.00% | 92.79% | 92.13% | 90.40% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 69.56% | 78.00% | 92.79% | 92.13% | 90.40% |
| Cost of Revenue | 115.62% | 147.69% | 200.75% | 128.06% | 185.63% |
| Gross Profit | 62.76% | 66.44% | 79.26% | 87.55% | 81.47% |
| SG&A Expenses | 75.27% | 61.04% | 51.01% | 43.30% | 45.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.58% | 81.60% | 85.24% | 64.43% | 54.29% |
| Operating Income | 303.56% | 68.60% | 136.17% | 295.22% | 193.01% |
| Income Before Tax | 272.40% | 77.16% | 507.05% | 371.99% | 151.21% |
| Income Tax Expenses | 43.63% | 939.40% | -94,168.56% | 933.23% | 1,306.90% |
| Earnings from Continuing Operations | 290.85% | -1.26% | 9,974.61% | 309.75% | 147.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 290.85% | -1.26% | 9,974.61% | 309.75% | 147.26% |
| EBIT | 303.56% | 68.60% | 136.17% | 295.22% | 193.01% |
| EBITDA | 303.56% | 68.62% | 136.09% | 294.52% | 193.39% |
| EPS Basic | 296.81% | 0.31% | 9,967.79% | 304.42% | 147.13% |
| Normalized Basic EPS | 448.07% | 80.00% | 505.43% | 365.37% | 151.10% |
| EPS Diluted | 300.00% | -6.14% | 12,050.00% | 325.00% | 140.98% |
| Normalized Diluted EPS | 449.05% | 78.05% | 506.02% | 362.65% | 146.05% |
| Average Basic Shares Outstanding | -1.53% | -1.57% | 0.22% | 1.39% | 0.32% |
| Average Diluted Shares Outstanding | -1.66% | -0.55% | 0.18% | 1.97% | 11.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |